Production (Stage)
Carisma Therapeutics, Inc.
CARM
$0.4297
-$0.0219-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.96M | 19.63M | 20.27M | 20.71M | 15.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.96M | 19.63M | 20.27M | 20.71M | 15.07M |
| Cost of Revenue | 51.37M | 59.67M | 63.51M | 71.74M | 74.95M |
| Gross Profit | -31.40M | -40.04M | -43.24M | -51.03M | -59.87M |
| SG&A Expenses | 18.60M | 20.14M | 23.53M | 24.95M | 25.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.97M | 79.81M | 87.04M | 96.68M | 100.34M |
| Operating Income | -50.00M | -60.18M | -66.77M | -75.97M | -85.27M |
| Income Before Tax | -50.77M | -60.48M | -64.00M | -72.70M | -81.32M |
| Income Tax Expenses | -- | -- | -197.00K | -197.00K | -109.00K |
| Earnings from Continuing Operations | -50.77 | -60.48 | -63.80 | -72.50 | -81.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.77M | -60.48M | -63.80M | -72.50M | -81.22M |
| EBIT | -50.00M | -60.18M | -66.77M | -75.97M | -85.27M |
| EBITDA | -47.68M | -56.83M | -63.37M | -72.61M | -81.44M |
| EPS Basic | -1.22 | -1.46 | -1.56 | -1.78 | -2.01 |
| Normalized Basic EPS | -0.73 | -0.88 | -0.98 | -1.12 | -1.26 |
| EPS Diluted | -1.22 | -1.46 | -1.56 | -1.78 | -2.01 |
| Normalized Diluted EPS | -0.73 | -0.88 | -0.98 | -1.12 | -1.26 |
| Average Basic Shares Outstanding | 166.66M | 165.82M | 164.46M | 163.16M | 161.87M |
| Average Diluted Shares Outstanding | 166.66M | 165.82M | 164.46M | 163.16M | 161.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |